✦ LIBER ✦

1866 THE EFFICIENCY OF SECOND-LINE CHEMOTHERAPY WITH GEMCITABINE AND PACLITAXEL FOR ADVANCED UROTHELIAL CARCINOMA RESISTANT TO CISPLATIN-BASED CHEMOTHERAPY

✍ Scribed by Nishihara, Chikako; Kuratsukuri, Katsuyuki; Iguchi, Taro; Tamada, Satoshi; Tanaka, Tomoaki; Uchida, Junji; Kawashima, Hidenori; Nakatani, Tatsuya

Book ID: 122343977
Publisher: Lippincott Williams and Wilkins
Year: 2013
Tongue: English
Weight: 130 KB
Volume: 189
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2013.02.2285

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of first-line chemotherap

Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma

✍ Urakami, Shinji; Fujii, Yasuhisa; Yamamoto, Shinya; Yuasa, Takeshi; Kitsukawa, S 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 195 KB

163 Second line treatment of advanced no

163 Second line treatment of advanced non-small-cell lung cancer after cisplatin-based chemotherapy with paclitaxel and gemcitabine

✍ Papadakis, E.; Kourousis, C.; Kakolyris, S.; Androulakis, N.; Dimopoulos, A.M.; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 165 KB

864 Combination of gemcitabine and pacli

864 Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy

✍ M. Ikeda; K. Matsumoto; K. Tabata; S. Minamida; T. Fujita; T. Satoh; M. Iwamura; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 16 KB

Impact of C-reactive protein kinetics on

Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin

✍ Kazutaka Saito; Shinji Urakami; Yoshinobu Komai; Yosuke Yasuda; Yuichi Kubo; Shi 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 304 KB

Paclitaxel-based second-line therapy for

Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1) : A clinical Phase II study

✍ Thomas Otto; Axel Bex; Susanne Krege; Peter H. Walz; Herbert Rübben 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

and an antimotility factor (acellular pertussis vaccine [APV]) in 18 School, Essen, Germany. patients with cisplatin-and methotrexate-resistant metastatic bladder carcinoma. Intramuscular injection of APV 3 times in the first week, on Days 1, 4, and 7, was

Phase II study of weekly chemotherapy wi

Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy

✍ Kiyoshi Mori; Yukari Kamiyama; Tetsuro Kondo; Yasuhiko Kano; Tetsuro Kodama 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 330 KB